Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma

Joris Veltman, Margaretha Lambers, Menno van Nimwegen, Rudi Hendriks, Henk Hoogsteden, Joost Hegmans, Joachim Aerts

Research output: Contribution to journalArticleAcademicpeer-review

90 Citations (Scopus)


BACKGROUND: Suppressive immune cells present in tumour microenvironments are known to augment tumour growth and hamper efficacy of antitumour therapies. The amino-bisphosphonate Zoledronic acid (ZA) is considered as an antitumour agent, as recent studies showed that ZA prolongs disease-free survival in cancer patients. The exact mechanism is a topic of debate; it has been suggested that ZA targets tumour-associated macrophages (TAMs). METHODS: We investigate the role of ZA on the myeloid differentiation to TAMs in murine mesothelioma in vivo and in vitro. Mice were intraperitoneally inoculated with a lethal dose of mesothelioma tumour cells and treated with ZA to determine the effects on myeloid differentiation and survival. RESULTS: We show that ZA impaired myeloid differentiation. Inhibition of myeloid differentiation led to a reduction in TAMs, but the number of immature myeloid cells with myeloid-derived suppressor cell (MDSC) characteristics was increased. In addition, ZA affects the phenotype of macrophages leading to reduced level of TAM-associated cytokines in the tumour microenvironment. No improvement of survival was observed. CONCLUSION: We conclude that ZA leads to a reduction in macrophages and impairs polarisation towards an M2 phenotype, but this was associated with an increase in the number of immature myeloid cells, which might diminish the effects of ZA on survival. British Journal of Cancer (2010) 103, 629-641. doi:10.1038/sj.bjc.6605814 www.bjcancer.com Published online 27 July 2010 (C) 2010 Cancer Research UK
Original languageUndefined/Unknown
Pages (from-to)629-641
Number of pages13
JournalBritish Journal of Cancer
Issue number5
Publication statusPublished - 2010

Cite this